Interactions between lithobid(lithium) and Celexa (citalopram)
lithium and citalopram (Major Drug-Drug)
MONITOR CLOSELY: Lithium may enhance the pharmacologic effects of selective serotonin reuptake inhibitors (SSRIs) and potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors. The exact mechanism by which this interaction occurs is unknown. Conversely, SSRIs may elevate the plasma concentrations of lithium and increase the risk of lithium toxicity. The interaction has been associated with fluoxetine, while citalopram and paroxetine reportedly do not cause the interaction. Excessive somnolence has been reported with lithium and fluvoxamine.
MANAGEMENT: Caution is advised if concomitant use of SSRIs and lithium is necessary. Lithium levels should be assessed regularly and the dosage adjusted accordingly. Close monitoring is recommended for signs and symptoms of lithium toxicity as well as excessive serotonergic activity such as CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia.
